|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
EP0584222B1
(en)
|
1991-05-10 |
1997-10-08 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
DE4221054A1
(de)
|
1992-06-30 |
1994-01-05 |
Herbst Bremer Goldschlaegerei |
Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben
|
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
|
CA2148484A1
(en)
|
1992-11-13 |
1994-05-26 |
Stewart Lyman |
Novel cytokine designated elk ligand
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
|
EP0672035A1
(en)
|
1993-10-01 |
1995-09-20 |
Novartis AG |
Pyrimidineamine derivatives and processes for the preparation thereof
|
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
CA2175215C
(en)
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
DE69423781T2
(de)
|
1993-12-17 |
2000-08-10 |
Novartis Ag |
Rapamycin-derivate als immunosuppressoren
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
AU2096895A
(en)
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
CA2189028A1
(en)
|
1994-04-15 |
1995-10-26 |
Gary M. Fox |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
|
ATE159257T1
(de)
|
1994-05-03 |
1997-11-15 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivate mit antiproliferativer wirkung
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
CA2216796C
(en)
|
1995-03-30 |
2003-09-02 |
Pfizer Inc. |
Quinazoline derivatives
|
|
NZ304859A
(en)
|
1995-04-03 |
2000-01-28 |
Novartis Ag |
4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof
|
|
WO1996033172A1
(en)
|
1995-04-20 |
1996-10-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
|
DK0833828T3
(da)
|
1995-06-09 |
2003-03-17 |
Novartis Ag |
Rapamycinderivater
|
|
KR100437582B1
(ko)
|
1995-07-06 |
2004-12-17 |
노파르티스 아게 |
피롤로피리미딘및그들의제조방법
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
|
ES2177925T3
(es)
|
1996-01-23 |
2002-12-16 |
Novartis Ag |
Pirrolopirimidinas y procedimientos para su preparacion.
|
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
CA2249739A1
(en)
|
1996-03-15 |
1997-09-25 |
Novartis Ag |
Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use
|
|
CA2249446C
(en)
|
1996-04-12 |
2008-06-17 |
Warner-Lambert Company |
Irreversible inhibitors of tyrosine kinases
|
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
ATE308527T1
(de)
|
1996-06-24 |
2005-11-15 |
Pfizer |
Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
US6258823B1
(en)
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
WO1998002434A1
(en)
|
1996-07-13 |
1998-01-22 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
|
CN1230185A
(zh)
|
1996-07-13 |
1999-09-29 |
葛兰素集团有限公司 |
双环芳杂环化合物用作蛋白质酪氨酸激酶的抑制剂
|
|
DE69712496T2
(de)
|
1996-07-18 |
2002-08-29 |
Pfizer |
Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
AU4055697A
(en)
|
1996-08-16 |
1998-03-06 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
BR9711223A
(pt)
|
1996-08-23 |
1999-08-17 |
Pfizer |
Derivados de cido arilsulfonilamino-hidrox mico
|
|
PT938486E
(pt)
|
1996-08-23 |
2008-03-27 |
Novartis Ag |
Pirrolopirimidinas substituídas e processos para a sua preparação
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US6251911B1
(en)
|
1996-10-02 |
2001-06-26 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
|
WO1998014449A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
|
AU5131998A
(en)
|
1997-01-06 |
1998-08-03 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
PL335027A1
(en)
|
1997-02-03 |
2000-03-27 |
Pfizer Prod Inc |
Derivatives of arylsulphonylamino hydroxamic acid
|
|
JP2001509805A
(ja)
|
1997-02-05 |
2001-07-24 |
ワーナー−ランバート・コンパニー |
細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
|
|
CA2279863A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
|
ID22809A
(id)
|
1997-02-11 |
1999-12-09 |
Pfizer |
Turunan-turunan asam arilsulfonil hidroksamat
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
|
YU1900A
(sh)
|
1997-08-08 |
2002-08-12 |
Pfizer Products Inc. |
Derivati ariloksiarilsulfonilamino hidroksaminske kiseline
|
|
AU1102399A
(en)
|
1997-10-21 |
1999-05-10 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
EP1053321A1
(en)
|
1998-02-09 |
2000-11-22 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
CA2322311C
(en)
|
1998-03-04 |
2009-10-13 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
CN1250526C
(zh)
|
1998-05-29 |
2006-04-12 |
苏根公司 |
吡咯取代的2－吲哚满酮蛋白激酶抑制剂
|
|
UA60365C2
(ru)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего
|
|
JP2002520324A
(ja)
|
1998-07-10 |
2002-07-09 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成インヒビター
|
|
CA2341409A1
(en)
|
1998-08-31 |
2000-03-09 |
Merck And Co., Inc. |
Novel angiogenesis inhibitors
|
|
EP1004578B1
(en)
|
1998-11-05 |
2004-02-25 |
Pfizer Products Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
|
WO2000059509A1
(en)
|
1999-03-30 |
2000-10-12 |
Novartis Ag |
Phthalazine derivatives for treating inflammatory diseases
|
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
|
CA2374851A1
(en)
|
1999-06-07 |
2000-12-14 |
Immunex Corporation |
Tek antagonists
|
|
WO2001003720A2
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
|
ATE264863T1
(de)
|
1999-08-24 |
2004-05-15 |
Ariad Gene Therapeutics Inc |
28-epirapaloge
|
|
KR100881105B1
(ko)
|
1999-11-05 |
2009-02-02 |
아스트라제네카 아베 |
Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
|
|
WO2001037820A2
(en)
|
1999-11-24 |
2001-05-31 |
Sugen, Inc. |
Ionizable indolinone derivatives and their use as ptk ligands
|
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
AU4328801A
(en)
|
2000-02-24 |
2001-09-03 |
Xcyte Therapies Inc |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
JP2003523768A
(ja)
|
2000-02-25 |
2003-08-12 |
イミュネックス・コーポレーション |
インテグリンアンタゴニスト
|
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
|
US7105530B2
(en)
|
2000-12-21 |
2006-09-12 |
Smithkline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
|
NZ543654A
(en)
|
2003-05-23 |
2009-05-31 |
Wyeth Corp |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
|
PL1646634T3
(pl)
|
2003-07-08 |
2009-04-30 |
Novartis Ag |
Zastosowanie rapamycyny i pochodnych rapamycyny w leczeniu utraty kości
|
|
EP1648900A4
(en)
|
2003-07-11 |
2010-02-10 |
Ariad Pharma Inc |
PHOSPHORUS MACROCYCLES
|
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
|
CA2533320A1
(en)
|
2003-08-15 |
2006-02-24 |
Novartis Ag |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
|
WO2005094314A2
(en)
|
2004-03-26 |
2005-10-13 |
The Burnham Institute |
Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
UA87153C2
(ru)
|
2004-08-26 |
2009-06-25 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
|
|
WO2006044453A1
(en)
|
2004-10-13 |
2006-04-27 |
Wyeth |
Analogs of 17-hydroxywortmannin as pi3k inhibitors
|
|
ES2657443T3
(es)
|
2005-03-25 |
2018-03-05 |
Gitr, Inc. |
Anticuerpos anti-GITR y usos de los mismos
|
|
EP1885369B1
(en)
|
2005-05-04 |
2015-09-23 |
Evotec AG |
Fused heterocyclic compounds, and compositions and uses thereof
|
|
PL2439273T3
(pl)
|
2005-05-09 |
2019-08-30 |
Ono Pharmaceutical Co., Ltd. |
Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20090012085A1
(en)
|
2005-09-20 |
2009-01-08 |
Charles Michael Baum |
Dosage forms and methods of treatment using a tyrosine kinase inhibitor
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
US8987474B2
(en)
|
2006-04-07 |
2015-03-24 |
University Of South Florida |
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
|
|
CL2007003520A1
(es)
|
2006-12-07 |
2008-08-22 |
Piramed Ltd Genentech Inc |
Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
|
|
WO2008124815A1
(en)
|
2007-04-10 |
2008-10-16 |
University Of South Florida |
Method of activating nk cells
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
RU2523890C2
(ru)
|
2007-09-12 |
2014-07-27 |
Дженентек, Инк. |
Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения
|
|
WO2009049098A2
(en)
|
2007-10-09 |
2009-04-16 |
Indiana University Research & Technology Corporation |
Materials and methods for regulating the activity of phosphatases
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
WO2009135000A2
(en)
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
|
JP2011526794A
(ja)
|
2008-07-02 |
2011-10-20 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
ＴＧＦ−βアンタゴニスト多重標的結合性分子
|
|
US9174969B2
(en)
|
2008-07-21 |
2015-11-03 |
University Of South Florida |
Indoline scaffold SHP-2 inhibitors and cancer treatment method
|
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
|
CN108752280A
(zh)
|
2009-08-17 |
2018-11-06 |
纪念斯隆-凯特琳癌症中心 |
热休克蛋白结合化合物、组合物以及其制备和使用方法
|
|
IN2012DN01920A
(ru)
|
2009-09-03 |
2015-07-24 |
Schering Corp |
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
PT2519543T
(pt)
|
2009-12-29 |
2016-10-07 |
Emergent Product Dev Seattle |
Proteínas de ligação de heterodímero e suas utilizações
|
|
US8637684B2
(en)
|
2010-05-12 |
2014-01-28 |
Wisconsin Alumni Research Foundation |
Tautomycetin and tautomycetin analog biosynthesis
|
|
WO2012041524A1
(en)
|
2010-10-01 |
2012-04-05 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
|
ES2764848T3
(es)
|
2010-12-20 |
2020-06-04 |
Incyte Holdings Corp |
N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
|
|
DK2937349T3
(en)
|
2011-03-23 |
2017-02-20 |
Amgen Inc |
CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
AU2013292309B2
(en)
|
2012-07-20 |
2017-05-25 |
Cleave Biosciences, Inc. |
Fused pyrimidines as inhibitors of p97 complex
|
|
US20150352131A1
(en)
|
2013-01-16 |
2015-12-10 |
Rhode Island Hospital |
Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
|
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
|
AU2014256984B2
(en)
|
2013-04-26 |
2019-02-14 |
Indiana University Research & Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
|
|
CA2953482A1
(en)
|
2013-07-03 |
2015-01-08 |
Indiana University Research & Technology Corporation |
Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
|
|
US9815813B2
(en)
|
2014-01-17 |
2017-11-14 |
Novartis Ag |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
CN105418632B
(zh)
|
2014-09-19 |
2020-02-21 |
上海创诺医药集团有限公司 |
噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
WO2016077793A1
(en)
|
2014-11-14 |
2016-05-19 |
Children's Hospital Medical Center |
Sos1 inhibitors for cancer treatment
|
|
PT3244891T
(pt)
|
2015-01-16 |
2022-10-20 |
Massachusetts Gen Hospital |
Compostos para melhorar o splicing do arnm
|
|
WO2016191328A1
(en)
|
2015-05-22 |
2016-12-01 |
Allosta Pharmaceuticals |
Methods to prepare and employ binding site models for modulation of phosphatase activity and selectivity determination
|
|
US10532977B2
(en)
|
2015-06-01 |
2020-01-14 |
Indiana University Research And Technology Corporation |
Small molecule inhibitors of protein tyrosine phosphatases and uses thereof
|
|
EP3310771B1
(en)
|
2015-06-19 |
2020-07-22 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
EP3310774B1
(en)
|
2015-06-19 |
2020-04-29 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
WO2017014323A1
(en)
|
2015-07-23 |
2017-01-26 |
Takeda Pharmaceutical Company Limited |
1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
|
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
|
WO2017079723A1
(en)
|
2015-11-07 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
|
US9932288B2
(en)
|
2015-12-09 |
2018-04-03 |
West Virginia University |
Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
|
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
|
JP7044375B2
(ja)
|
2016-05-31 |
2022-03-30 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｐｔｐｎ１１の複素環式阻害剤
|
|
KR20230109185A
(ko)
|
2016-06-07 |
2023-07-19 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
|
AU2017296289A1
(en)
|
2016-07-12 |
2019-01-31 |
Revolution Medicines, Inc. |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
|
|
WO2018057884A1
(en)
|
2016-09-22 |
2018-03-29 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
TW201819386A
(zh)
|
2016-10-24 |
2018-06-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
|
US10898487B2
(en)
|
2016-12-22 |
2021-01-26 |
Boehringer Ingelheim International Gmbh |
Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
|
|
WO2018129402A1
(en)
|
2017-01-06 |
2018-07-12 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
|
JP2020504136A
(ja)
|
2017-01-10 |
2020-02-06 |
ノバルティス アーゲー |
Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬
|
|
AU2018210770B2
(en)
|
2017-01-23 |
2022-03-24 |
Revolution Medicines, Inc. |
Bicyclic compounds as allosteric SHP2 inhibitors
|
|
MX2019008696A
(es)
|
2017-01-23 |
2019-09-13 |
Revolution Medicines Inc |
Compuestos de piridina como inhibidores de shp2 alostericos.
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CA3056970A1
(en)
|
2017-03-21 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
2-methyl-quinazolines
|
|
TWI664175B
(zh)
|
2017-03-23 |
2019-07-01 |
大陸商北京加科思新藥研發有限公司 |
用於作為shp2抑制劑之新穎雜環衍生物
|
|
WO2018204416A1
(en)
|
2017-05-02 |
2018-11-08 |
Revolution Medicines, Inc. |
Rapamycin analogs as mtor inhibitors
|
|
WO2018218133A1
(en)
|
2017-05-26 |
2018-11-29 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
BR112020004246A2
(pt)
|
2017-09-07 |
2020-09-01 |
Revolution Medicines, Inc. |
composições inibidoras de shp2 e métodos para o tratamento de câncer
|
|
MA50245A
(fr)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals Inc |
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
|
|
EP3687997A1
(en)
|
2017-09-29 |
2020-08-05 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
PT3728254T
(pt)
*
|
2017-12-21 |
2023-05-02 |
Boehringer Ingelheim Int |
Piridopirimidinonas substituídos com benzilamino e derivados como inibidores de sos1
|
|
US11426422B2
(en)
|
2018-01-30 |
2022-08-30 |
Research Development Foundation |
SHP2 inhibitors and methods of use thereof
|
|
KR102614939B1
(ko)
|
2018-02-13 |
2023-12-19 |
블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 |
피리미딘-융합고리 화합물 및 그의 제조방법과 용도
|
|
US20200392161A1
(en)
|
2018-02-21 |
2020-12-17 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
KR20200127005A
(ko)
|
2018-03-02 |
2020-11-09 |
오쓰까 세이야꾸 가부시키가이샤 |
약제학적 화합물
|
|
EP3768664A4
(en)
|
2018-03-21 |
2021-12-15 |
Chengdu SYNBLic Therapeutics Inc., Ltd. |
SHP2 INHIBITORS AND THEIR USES
|
|
RU2020134302A
(ru)
|
2018-03-21 |
2022-04-22 |
Рилэй Терапьютикс, Инк. |
Ингибиторы shp2 фосфатазы и способы их применения
|
|
WO2019183364A1
(en)
|
2018-03-21 |
2019-09-26 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
|
CN112203689A
(zh)
|
2018-04-10 |
2021-01-08 |
锐新医药公司 |
治疗癌症的shp2抑制剂组合物和方法
|
|
EP3781565A1
(en)
|
2018-04-18 |
2021-02-24 |
Bayer Pharma Aktiengesellschaft |
2-methyl-aza-quinazolines
|
|
MX2020011565A
(es)
|
2018-05-01 |
2021-01-29 |
Revolution Medicines Inc |
Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
|
|
KR20210018243A
(ko)
|
2018-05-01 |
2021-02-17 |
레볼루션 메디슨즈, 인크. |
mTOR 억제제로서의 C26-연결된 라파마이신 유사체
|
|
AU2019263294B2
(en)
|
2018-05-02 |
2024-03-21 |
Navire Pharma, Inc. |
Substituted heterocyclic inhibitors of PTPN11
|
|
WO2019233810A1
(en)
|
2018-06-04 |
2019-12-12 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
|
JP7174143B2
(ja)
|
2018-07-24 |
2022-11-17 |
大鵬薬品工業株式会社 |
Ｓｈｐ２活性を阻害するヘテロ二環性化合物
|
|
WO2020033286A1
(en)
|
2018-08-06 |
2020-02-13 |
Purdue Research Foundation |
Novel sesquiterpenoid analogs
|
|
CR20210132A
(es)
|
2018-08-10 |
2021-07-20 |
Navire Pharma Inc |
Inhibidores de ptpn11
|
|
CN113227103A
(zh)
|
2018-09-18 |
2021-08-06 |
尼坎医疗公司 |
作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物
|
|
CN112839935A
(zh)
|
2018-09-26 |
2021-05-25 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
CN113473990A
(zh)
|
2018-10-08 |
2021-10-01 |
锐新医药公司 |
用于治疗癌症的shp2抑制剂组合物
|
|
CN111295384B
(zh)
|
2018-10-10 |
2022-08-12 |
江苏豪森药业集团有限公司 |
双环类衍生物抑制剂、其制备方法和应用
|
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
|
JP7449282B2
(ja)
|
2018-10-17 |
2024-03-13 |
アレイ バイオファーマ インコーポレイテッド |
タンパク質チロシンホスファターゼ阻害薬
|
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
US20230029385A1
(en)
|
2019-10-15 |
2023-01-26 |
Bayer Aktiengesellschaft |
2-methyl-aza-quinazolines
|
|
PE20230249A1
(es)
*
|
2019-11-08 |
2023-02-07 |
Revolution Medicines Inc |
Compuestos de heteroarilo biciclicos y usos de estos
|